In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5
- 18 November 2010
- journal article
- case report
- Published by Springer Science and Business Media LLC in Pituitary
- Vol. 14 (2), 141-147
- https://doi.org/10.1007/s11102-010-0271-2
Abstract
Thyrotropin-secreting pituitary adenomas (TSHomas) are a rare cause of hyperthyroidism and account for less than 2% of pituitary adenomas. Medical therapy with somatostatin analogues (SSAs) effectively reduces TSH secretion in approximately 80% of patients and induces shrinkage in about 45% of tumors. According with previous data, resistance to SSA treatment might be due to heterogeneity in somatostatin receptors (SSTRs) expression. We report the case of TSHoma in a 41-year-old man treated with octreotide LAR that caused a dramatic decrease of TSH and thyroid hormones and tumor shrinkage already after 3 months of pre-surgical therapy. In search of potential molecular determinants of octreotide effectiveness, we measured, in primary cultures from this tumor, SSTR and dopamine D2 receptor (D2R) expression, and octreotide and/or cabergoline effects on TSH secretion and cell proliferation. SSTR5 and D2R expression was higher than SSTR2. Octreotide significantly inhibited TSH secretion more effectively than cabergoline (P < 0.001), whereas the combined treatment was comparable with cabergoline alone. Similarly, octreotide resulted more effective than cabergoline on cell proliferation, while the combination did not show any additive or synergistic effects. In conclusion, the significant antisecretive and antiproliferative effect of octreotide in this patient might be related to the high expression of SSTR5, in the presence of SSTR2. After reviewing the literature, indeed, in line with previous observations, we hypothesize that SSTR5/SSTR2 ratio in TSHomas may represent a useful marker in predicting the outcome of therapy with SSAs. The role of D2R should be further explored considering that the presence of D2R can influence SSTRs functionality.Keywords
This publication has 38 references indexed in Scilit:
- Expression Analysis of Dopamine Receptor Subtypes in Normal Human Pituitaries, Nonfunctioning Pituitary Adenomas and Somatotropinomas, and the Association between Dopamine and Somatostatin Receptors with Clinical Response to Octreotide-LAR in AcromegalyJournal of Clinical Endocrinology & Metabolism, 2009
- Overexpression of Stromal Cell–Derived Factor 1 and Its Receptor CXCR4 Induces Autocrine/Paracrine Cell Proliferation in Human Pituitary AdenomasClinical Cancer Research, 2008
- Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2: Co-immunoprecipitation and fluorescence resonance energy transfer analysisCellular Signalling, 2007
- Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitroJournal of Molecular Endocrinology, 2005
- Long-Term Treatment with Bromocriptine of a Plurihormonal Pituitary Adenoma Secreting Thyrotropin, Growth Hormone and Prolactin.Endocrine Journal, 1999
- STUDIES OF TWO THYROTROPHIN‐SECRETING PITUITARY ADENOMAS: EVIDENCE FOR DOPAMINE RECEPTOR DEFICIENCYClinical Endocrinology, 1989
- Response of Thyrotropin-Secreting Pituitary Adenomas to a Long-Acting Somatostatin AnalogueThe New England Journal of Medicine, 1987
- Inappropriate Secretion of Thyrotropin by the PituitaryHormone Research, 1987
- HYPERPROLACTINAEMIA, AMENORRHOEA AND GALACTORRHOEA DUE TO A PITUITARY THYROTROPH ADENOMAClinical Endocrinology, 1985
- Human Pituitary Adenomas with Hypersecretion of TSH and Prolactin - Evidence that receptor sites for dopamin may be absent on TSH producing while present on prolactin producing cellsHormone and Metabolic Research, 1979